Ipsen’s cabozantinib has been recommended by the National Institute for Health and Care Excellence (NICE) as an option for patients with previously treated advanced hepatocellular carcinoma (HCC).

The US government has announced the ten drugs selected for the first round of pricing negotiations under President Biden’s Inflation Reduction Act (IRA). The IRA allows Medicare, the government health ...

CMS deputy administrator and director of the CMS Innovation Center, Liz Fowler, said the models would “test strategies to make it easier for Medicare patients to afford and access needed prescriptions ...

World Hepatitis Day takes place today, with this year’s theme, ‘I can’t wait’, highlighting the need to accelerate the fight against viral hepatitis to reach the 2030 elimination target. The campaign, ...

German company Merck KGaA has signed an exclusive licence agreement with Swiss biopharma company Debiopharm for its late-stage oncology asset xevinapant. Xevinapant is a potentially first-in-class ...

As technology advances there is a growing array of MedTech solutions – wearables, voice-activated devices, telehealth, etc. – to better support patients in their daily lives. However, MedTech research ...

AstraZeneca (AZ) and Merck’s – known as MSD outside the US and Canada – Lynparza (olaparib) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a ...

Gilead and EVOQ Therapeutics (EVOQ) have entered into a collaboration and licensing agreement aimed at advancing immunotherapies for the treatment of rheumatoid arthritis (RA) and lupus. Under the ...

Professor Susan Short, co-author of the study from the University of Leeds, said: “We desperately need new treatment avenues for these aggressive brain tumours. Targeting developmental genes like the ...

Merck & Co – known as MSD outside the US and Canada – and Moderna have announced positive phase 2b trial results investigating the use of their personalised mRNA cancer vaccine, mRNA-4157/V940, in ...

New treatment option for high-risk patientsThe patients had been treated a median of 12 times with BCG but were still seeing disease progression. Keytruda given every three weeks resulted in a ...

Professor Jenny Harries, chief executive of UKHSA, said: “Antimicrobial resistance (AMR) is not a crisis of the future, but one that is very much with us right now… Unless action is taken the ...